Announcement: “New Publication: Bulletin MADRAC - August 2016”

Kadar pengguna: 1 / 5

bintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

MADRAC Bulletin - August 2016

Annual Report for 2015
   ▪ Spontaneous Adverse Drug Reactions (ADRs) including Adverse Events Following Immunisation (AEFIs) Reported in Malaysia
Regulatory Matters
   ▪ Bisphosphonates: Risk of osteonecrosis of the external auditory canal.
   ▪ Minyak Cajeput (Melaleuca leucodendran): Risk of glottal spasm and bronchospasm.
   ▪ Glivec (imatinib) and Tasigna (nilotinib): Risk of Hepatitis B Virus reactivation.
   ▪ Adempas (riociguat): New contraindication for patients with pulmonary hypertension associated  with idiopathic interstitial pneumonia.
What’s New?
▪ Consumer Side Effect Reporting Form (ConSERF)

 



 
 
  DOWNLOAD PDF



  MORE MADRAC BULLETIN

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Isnin 23 Mei 2022, 15:55:45.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search

Choose Your Language

Menu Utama